Dillon & Associates’s Express Scripts Holding Company ESRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2018
Q4
Sell
-4,790
Closed -$455K 73
2018
Q3
$455K Sell
4,790
-50
-1% -$4.26K 0.15% 53
2018
Q2
$373K Sell
4,840
-275
-5% -$20.6K 0.14% 56
2018
Q1
$353K Buy
5,115
+100
+2% +$7.63K 0.14% 57
2017
Q4
$376K Sell
5,015
-35
-0.7% -$2.24K 0.14% 57
2017
Q3
$318K Buy
5,050
+15
+0.3% +$932 0.13% 59
2017
Q2
$322K Sell
5,035
-1,700
-25% -$107K 0.13% 59
2017
Q1
$445K Buy
6,735
+355
+6% +$24.4K 0.19% 57
2016
Q4
$440K Buy
6,380
+710
+13% +$50.9K 0.2% 56
2016
Q3
$403K Buy
5,670
+345
+6% +$25.8K 0.19% 58
2016
Q2
$405K Buy
5,325
+580
+12% +$42.6K 0.19% 57
2016
Q1
$327K Buy
4,745
+75
+2% +$5.39K 0.15% 59
2015
Q4
$406K Buy
4,670
+205
+5% +$17.6K 0.2% 54
2015
Q3
$362K Buy
4,465
+645
+17% +$56.2K 0.18% 57
2015
Q2
$340K Buy
3,820
+455
+14% +$39.7K 0.17% 55
2015
Q1
$293K Buy
3,365
+785
+30% +$65.8K 0.14% 57
2014
Q4
$219K Buy
+2,580
New +$202K 0.11% 61

Other funds holding ESRX

Dillon & Associates's ESRX Position: Q4 2018 in Review

Dillon & Associates sold out of Express Scripts Holding Company (ESRX) in Q4 2018, closing a stake of 4,790 shares — an estimated $455K sold.

Dillon & Associates first reported a position in ESRX in Q4 2014 and held it in 16 quarters. The position peaked at $455K in Q3 2018. 16 funds tracked by Wall St. Rank hold ESRX as of Q4 2018.

  • Dillon & Associates reported no remaining Express Scripts Holding Company position as of Q4 2018 after selling out during the quarter.
  • Dillon & Associates sold 4,790 Express Scripts Holding Company shares in Q4 2018, an estimated $455K.
  • Dillon & Associates first reported a position in Express Scripts Holding Company in Q4 2014 and held it in 16 quarters.
  • Dillon & Associates's Express Scripts Holding Company position peaked at $455K in Q3 2018.
  • 16 funds tracked by Wall St. Rank held Express Scripts Holding Company as of Q4 2018.

Based on Dillon & Associates's 13F filing for Q4 2018, filed 14 Feb 2019.